Analysts: Oracle Is Still Intact and 3 More Research Notes to Explore
Oracle (NASDAQ:ORCL): Following in-line Q4 adjusted EPS but slightly lower than expected revenue, BMO Capital thinks the company’s large database business is relatively intact, while its license sales growth was “decent” in the rest of the world. The firm reduced its price target on the stock to $39 from $43, but keeps an Outperform rating on the shares.
Jazz Pharmaceuticals (NASDAQ:JAZZ): Brean Capital has raised its price target to $93 from $88 after recent meetings with Jazz management, and increased its estimates to the high end of guidance for Erwinaze while noting the company is working toward a more unified treatment for the drug with adult patient groups. Shares are Buy rated.
Bed Bath & Beyond (NASDAQ:BBBY): Credit Suisse sees Bed Bath & Beyond as one of the cheapest ways to play the strong housing market, and believes expectations are low ahead of next week’s report and that commentary regarding the dividend, margin stability, and World Markets rollout will send shares higher. The firm rates the company with an Outperform and a $75 price target.
Facebook (NASDAQ:FB): After Facebook’s launch of 15 second videos for Instagram users, Topeka expects Facebook to incorporate video ads into Instagram, which will enable the company to capture a meaningful slice of traditional media ad budgets. The firm reiterates a Buy rating on the stock.
Don’t Miss: SoftBank: Sprint Acquisition to Close by July.